News - BioSpace
Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM and her talks with Biogen, Gilead, Novavax and more; …
BioSpace: Biotech, Pharmaceutical and Clinical Research News
2010年12月11日 · 2024 was a tough year for the biopharma industry, with several companies cutting hundreds or even thousands of employees. Follow along as BioSpace tracks job cuts …
Texas Biomedical Research Institute enters landmark ... - BioSpace
2024年10月29日 · Under the partnership, Texas Biomed will deliver preclinical research and resources to help develop vaccines for reducing global epidemic and pandemic risks.
Regeneron Acquisition of Oxular Wipes Out Oxular Workforce
2025年1月3日 · 2024 was a tough year for the biopharma industry, with several companies including Bayer, Bristol Myers Squibb and Johnson & Johnson are cutting hundreds or even …
BioSpace Announces 2025 Best Places to Work in Biopharma
2024年11月12日 · Based on input from over 3,600 life sciences professionals, BioSpace has named 50 companies with U.S. operations as its 2025 Best Places to Work, a group that …
After Decades of Failure, First Disease-Modifying Huntington’s ...
2024年11月11日 · In September, Prilenia announced that the European Medicines Agency had accepted its marketing authorization application for pridopidine in Huntington’s disease. …
Join Our Team - BioSpace
BioSpace is the digital hub for life sciences news and jobs. Our mission is to provide essential insights, tools, and opportunities to connect the innovative organizations and talented …
About Us - BioSpace
BioSpace is the digital hub for life science news and jobs.We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who …
BioSpace - BioSpace
2024年7月31日 · BioSpace is the digital hub for life science news and jobs.We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals …
CAR T for Lupus Takes Center Stage at ACR 2024 - BioSpace
2024年11月19日 · While CAR T cell therapies are pricey—BMS’s Breyanzi is over $480,000 for one suspension—the potential to have a one-time infusion for a long-lasting, drug-free …